Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib in Advanced Hepatocellular Carcinoma
NCT04358185Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Dec 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in hepatocellular carcinoma (HCC), sponsored by Imperial College London. Primary endpoints: Adverse Events at 1 year and Objective Response Rate at 1 year. Started Dec 2018; status: completed.
02
Drugs
itacitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04358185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358185.